BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND TCF3, E2A, 6929, ENSG00000071564, P15923, MGC129648, MGC129647, ITF1
16 results:

  • 1. Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic prostate cancer Treated with Curative Intent: A Systematic Review.
    Marra G; van Leenders GJLH; Zattoni F; Kesch C; Rajwa P; Cornford P; van der Kwast T; van den Bergh RCN; Briers E; Van den Broeck T; De Meerleer G; De Santis M; Eberli D; Farolfi A; Gillessen S; Grivas N; Grummet JP; Henry AM; Lardas M; Lieuw M; Linares Espinós E; Mason MD; O'Hanlon S; van Oort IM; Oprea-Lager DE; Ploussard G; Rouvière O; Schoots IG; Stranne J; Tilki D; Wiegel T; Willemse PM; Mottet N; Gandaglia G;
    Eur Urol; 2023 Jul; 84(1):65-85. PubMed ID: 37117107
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of tcf3.
    Lin Y; Zhan M; Xu B
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7663-7677. PubMed ID: 37000263
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. MEX3D is an oncogenic driver in prostate cancer.
    Shao L; Wang J; Karatas O; Ittmann M
    Prostate; 2021 Nov; 81(15):1202-1213. PubMed ID: 34455614
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in prostate cancer Cells.
    Wen F; Sun X; Sun C; Dong Z; Jia G; Bao W; Yu H; Yang C
    Mol Cancer Res; 2021 Jul; 19(7):1113-1122. PubMed ID: 33771884
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
    PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Germline Variants of prostate cancer in Japanese Families.
    Hayano T; Matsui H; Nakaoka H; Ohtake N; Hosomichi K; Suzuki K; Inoue I
    PLoS One; 2016; 11(10):e0164233. PubMed ID: 27701467
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome.
    Du M; Yuan T; Schilter KF; Dittmar RL; Mackinnon A; Huang X; Tschannen M; Worthey E; Jacob H; Xia S; Gao J; Tillmans L; Lu Y; Liu P; Thibodeau SN; Wang L
    Hum Mol Genet; 2015 Jan; 24(1):154-66. PubMed ID: 25149474
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Increased expression of bHLH transcription factor e2a (tcf3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis.
    Patel D; Chaudhary J
    Biochem Biophys Res Commun; 2012 May; 422(1):146-51. PubMed ID: 22564737
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis.
    Skotheim RI; Thomassen GO; Eken M; Lind GE; Micci F; Ribeiro FR; Cerveira N; Teixeira MR; Heim S; Rognes T; Lothe RA
    Mol Cancer; 2009 Jan; 8():5. PubMed ID: 19152679
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumor classification ranking from microarray data.
    Hewett R; Kijsanayothin P
    BMC Genomics; 2008 Sep; 9 Suppl 2(Suppl 2):S21. PubMed ID: 18831787
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ID1-, ID2-, and ID3-regulated gene expression in e2a positive or negative prostate cancer cells.
    Asirvatham AJ; Carey JP; Chaudhary J
    Prostate; 2007 Sep; 67(13):1411-20. PubMed ID: 17639499
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. FB1, an e2a fusion partner in childhood leukemia, interacts with U19/EAF2 and inhibits its transcriptional activity.
    Jiang F; Ai J; Xiao W; Wang Z
    Cancer Lett; 2007 Aug; 253(2):265-72. PubMed ID: 17395368
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Chromatin structural elements and chromosomal translocations in leukemia.
    Zhang Y; Rowley JD
    DNA Repair (Amst); 2006 Sep; 5(9-10):1282-97. PubMed ID: 16893685
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer.
    Leman ES; Arlotti JA; Dhir R; Greenberg N; Getzenberg RH
    J Cell Biochem; 2002; 86(2):203-12. PubMed ID: 12111990
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.